Viewing data from:

VYFEMLA

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE | A201886 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: TRI-NORINYL 28-DAY(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Vyfemla (2023)

Total Spending

$24K

Total Claims

463

Beneficiaries

128

Avg Cost/Unit

$0.78

Spending Trend

$42K(2019)→$40K(2020)→$28K(2021)→$27K(2022)→$24K(2023)

YoY Change:-6.2%

5yr CAGR:-1.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG;0.4MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Sep 26, 2013

No patent or exclusivity listings for this strength.